SuperworthAlector price to sales ratio ALEC
Market value divided by revenue over the last twelve months, since 2020.
- Today, Oct 23, 2026
- 14.7×
- 7-year median
- 5.8×
- Against its 7-year history
- 73rd
- percentile: 0 is its lowest day, 100 its highest
- 7-year range
- 0.9× to 163×
- Peer median
- 2.2×
Alector's price to sales ratio is 14.7× as of Oct 23, 2026.
That is above its 7-year median of 5.8×, higher than on 73% of days in the last 7 years.
Over that time it ranged from 0.9× in Apr 2025 to 163× in Jul 2021.
The median for 10 healthcare stocks of a similar size is 2.2×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 14.7× | 2.4× | 19.8× |
| 2025 | 2.3× | 0.9× | 4.1× |
| 2024 | 2.8× | 2.8× | 10.6× |
| 2023 | 7.0× | 3.8× | 7.2× |
| 2022 | 5.7× | 2.3× | 7.4× |
| 2021 | 8.5× | 8.0× | 163× |
| 2020 | 53.9× | 39.2× | 115× |
Against its peers
Companies in Healthcare nearest Alector's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| ALECAlector | 14.7× |
| PLXProtalix BioTherapeutics | 2.5× |
| PDEXPro DEX | 2.6× |
| NATRNatures Sunshine Products | 0.4× |
| ELMDElectromed | 3.0× |
| UTMDUtah Medical Products | 6.5× |
| INFUInfuSystem | 1.9× |
| VMDViemed Healthcare | 1.2× |
| EMBCEmbecta | 0.4× |
| KEQUKewaunee Scientific | 0.3× |
| ICCCImmucell | 3.0× |
| Peer median | 2.2× |
Where Alector ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Alector
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.